Active Clinical Trials

Based on positive results of previous MAR-T cell product candidates in various blood cancers and solid tumors, we are currently investigating our lead product candidate, MT-601, in a Phase 1 multi-center clinical trial (APOLLO study). Our APOLLO study is enrolling patients with lymphoma who relapsed or are ineligible to receive anti-CD19 CAR-T cell therapy.